|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,137.50 JPY | -0.42% |
|
+0.85% | +2.13% |
| 06-30 | Trump's push for the world's lowest drug prices hits snag with mid-sized companies | RE |
| 06-26 | Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets | MT |
| Market Cap | 3,829B 23.54B 20.65B 19.06B 17.62B 33.39B 2,254B 34.06B 229B 89.04B 1,103B 88.41B 86.47B | P/E 2027 * |
11.1x | P/E 2028 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 3,753B 23.07B 20.23B 18.68B 17.26B 32.72B 2,209B 33.37B 225B 87.26B 1,081B 86.63B 84.73B | EV / Sales 2027 * |
1.67x | EV / Sales 2028 * | 1.66x |
| Free-Float |
97.66% | Yield 2027 * |
3.75% | Yield 2028 * | 3.86% |
Last Transcript: Astellas Pharma Inc.
| 1 day | -0.42% | ||
| 1 week | +0.85% | ||
| Current month | -1.72% | ||
| 1 month | -0.54% | ||
| 3 months | -18.54% | ||
| 6 months | -3.41% | ||
| Current year | +2.13% |
| 1 week | 2,130 |  | 2,216.5 |
| 1 month | 2,041 | | 2,216.5 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,368 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 09/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 31/10/2023 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Enyedy
BRD | Director/Board Member | 61 | 18/06/2025 |
Andreas Busch
BRD | Director/Board Member | 62 | 18/06/2025 |
Tomoko Aramaki
BRD | Director/Board Member | 57 | 31/05/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.42% | +0.85% | +56.59% | +3.71% | 23.64B | |
| -0.07% | +0.07% | +54.37% | +168.07% | 1,084B | |
| -1.10% | -0.90% | +66.80% | +63.42% | 634B | |
| -0.32% | -3.37% | +32.34% | +87.57% | 447B | |
| -0.04% | -1.99% | +28.73% | +26.18% | 330B | |
| -7.20% | -9.38% | +27.14% | +29.41% | 295B | |
| -1.11% | -2.89% | +27.44% | +44.93% | 285B | |
| -0.93% | -3.57% | -27.74% | -39.70% | 218B | |
| -1.21% | -2.77% | +22.69% | +61.88% | 199B | |
| -1.27% | +2.32% | +18.62% | +77.46% | 169B | |
| Average | -1.37% | +2.40% | +30.70% | +52.29% | 368.35B | |
| Weighted average by Cap. | -1.10% | +2.47% | +39.09% | +83.73% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,250B 13.83B 12.13B 11.2B 10.35B 19.62B 1,325B 20.01B 135B 52.32B 648B 51.95B 50.81B | 2,072B 12.74B 11.17B 10.31B 9.53B 18.06B 1,220B 18.43B 124B 48.17B 597B 47.83B 46.78B |
| Net income | 345B 2.12B 1.86B 1.72B 1.59B 3B 203B 3.06B 20.62B 8.01B 99.27B 7.96B 7.78B | 325B 2B 1.75B 1.62B 1.49B 2.83B 191B 2.89B 19.43B 7.55B 93.55B 7.5B 7.33B |
| Net Debt | -76.78B -472M -414M -382M -353M -669M -45.2B -683M -4.6B -1.79B -22.12B -1.77B -1.73B | -391B -2.41B -2.11B -1.95B -1.8B -3.41B -230B -3.48B -23.41B -9.1B -113B -9.03B -8.83B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/07/26 | JP¥2,137.50 | -0.42% | 4,773,500 |
| 08/07/26 | JP¥2,146.50 | -1.29% | 6,198,900 |
| 07/07/26 | JP¥2,174.50 | -1.52% | 6,880,100 |
| 06/07/26 | JP¥2,208.00 | +2.60% | 4,506,600 |
| 03/07/26 | JP¥2,152.00 | +0.58% | 5,173,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
